T-cell-immunity During Standard Radiotherapy in Localised Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01376674
Recruitment Status : Completed
First Posted : June 20, 2011
Last Update Posted : August 16, 2013
Information provided by (Responsible Party):
Franziska Eckert, University Hospital Tuebingen

Brief Summary:

Immunological effects of radiotherapy have been described before, but not evaluated in a time-dependant manner.

In order to identify a possible time frame for combination therapies, white blood cells are isolated of samples taken at different time points before during and after standard radiotherapy in patients with localised prostate cancer. The overall activity of the T-cell-system as well as tumor-specific T-cell-response are evaluated.

Condition or disease
Prostate Cancer

Study Type : Observational
Actual Enrollment : 22 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Changes of T-cell-immune-status During Curative Radiotherapy in Prostate Cancer
Study Start Date : March 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer
U.S. FDA Resources

Primary Outcome Measures :
  1. T-cell-immunity in time-course [ Time Frame: During and 3-6 months after radiotherapy ]

Biospecimen Retention:   Samples With DNA
Peripheral blood mononuclear cells and serum are frozen and stored.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients undergoing standard radiotherapy for localised prostate cancer at the University Hospital of Tuebingen

Inclusion Criteria:

  • Localised prostate cancer (node negative)
  • definitive radiotherapy
  • informed consent

Exclusion Criteria:

  • medication including steroids or immunosuppressants

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01376674

Department of Radiation Oncology
Tuebingen, Germany, D-72076
Sponsors and Collaborators
University Hospital Tuebingen
Principal Investigator: Cihan Gani, M.D. University Hospital Tuebingen
Study Director: Franziska Eckert, MD University Hospital Tuebingen

Responsible Party: Franziska Eckert, M.D., University Hospital Tuebingen Identifier: NCT01376674     History of Changes
Other Study ID Numbers: UKT_RO_01
First Posted: June 20, 2011    Key Record Dates
Last Update Posted: August 16, 2013
Last Verified: August 2013

Keywords provided by Franziska Eckert, University Hospital Tuebingen:
prostate cancer

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases